Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells-Reference-Cited by-同舟云学术

Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells

Published:2018-09 Issue: Volume:431 Page:54-63
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Li Ailin,Barsoumian Hampartsoum B.,Schoenhals Jonathan E.,Cushman Taylor R.,Caetano Mauricio S.,Wang Xiaohong,Valdecanas David R.,Niknam Sharareh,Younes Ahmed I.,Li Guang,Woodward Wendy A.,Cortez Maria Angelica,Welsh James W.

Funder

National Natural Science Foundation of China

Susan and Peter Goodwin Foundation

Mabuchi Research fund

Orr Family Foundation

Wiegand Foundation

Doctors Cancer Foundation

Lung Cancer Research Foundation

Cancer Center Support

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?;O'Donnell;Genome Medicine,2016

2. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol.,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors;Pitt;Immunity,2016

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer;Journal of Thoracic Oncology;2024-08

2. The significant role of amino acid metabolic reprogramming in cancer;Cell Communication and Signaling;2024-07-29

3. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302);BMC Cancer;2024-07-25

4. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy;Journal of Experimental & Clinical Cancer Research;2024-03-06

5. Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions;iScience;2023-10